Top

Diagnostic Pathology

Published in:

Open Access 01-12-2013 | Research

The expression of V-ATPase is associated with drug resistance and pathology of non-small-cell lung cancer

Authors: Qiang Lu, Sha Lu, Lijun Huang, Ting Wang, Yi Wan, Chang Xi Zhou, Cunhai Zhang, Zhipei Zhang, Xiaofei Li

Published in: Diagnostic Pathology | Issue 1/2013

Abstract

Objective

This article aims to investigate the expression of vacuolar-H + −ATPase (V-ATPase) in non-small cell lung cancer (NSCLC) and its variations with pathological type and grade. Furthermore, to evaluate the chemotherapy drug sensitivity of different cancer tissues as well as its correlation with V-ATPase expression in NSCLC.

Methods

V-ATPase expression was examined in 92 NSCLC tissue samples using the immunohistochemical Envision method and immunofluorescence assay. The location of V-ATPase expression was observed by confocal laser scanning microscopy and the difference of its expression rate was evaluated. The sensitivity of cancer tissues to chemotherapy drug was examined using MTT assay and its correlation with the V-ATPase expression was tested in NSCLC by Spearman rank correlation analysis.

Results

V-ATPase expression was mainly localized in the cell membrane and cytoplasm. The expression rate of V-ATPase was 71.43% in squamous cell lung cancer, significantly lower than that of the lung adenocarcinoma (83.72%, P = 0.000). In different pathological grades of squamous cell lung cancer, the expression rate of V-ATPase was 58.33% in grade II, significantly lower than that of the grade III (84.00%, P = 0.014). The expression rate of V-ATPase in grade II lung adenocarcinoma was 76.67%, significantly lower than that of the grade ΙΙΙ adenocarcinoma (100.0%, P = 0.012). Correlation analysis showed that the sensitivity of NSCLC tissues to cyclophosphamide, gemcitabine, doxorubicin, paclitaxel and cisplatin was significantly correlated with the V-ATPase expression rate (P < 0.05).

Conclusions

V-ATPase was overexpressed in NSCLC. The expression of V-ATPase was related to the pathological type and grade of cancer and was likely associated with chemotherapy drug resistance in NSCLC.

Virtual slides

The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/7515811511020000

Available only for authorised users

Owonikoko TK, Behera M, Chen Z, Bhimani C, Curran WJ, Khuri FR, Ramalingam SS: A systematic analysis of efficacy of second-line chemotherapy in sensitive and refractory small-cell lung cancer. J Thorac Oncol. 2012, 7: 866-872. 10.1097/JTO.0b013e31824c7f4b.PubMedCentralCrossRefPubMed

Ho CC, Kuo SH, Huang PH, Huang HY, Yang CH, Yang PC: Caveolin-1 expression is significantly associated with drug resistance and poor prognosis in advanced non-small cell lung cancer patients treated with gemcitabine-based chemotherapy. Lung Cancer. 2008, 59: 105-110. 10.1016/j.lungcan.2007.07.024.CrossRefPubMed

Ohashi K, Sequist LV, Arcila ME, Moran T, Chmielecki J, Lin YL, Pan Y, Wang L, de Stanchina E, Shien K, et al.: Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1. Proc Natl Acad Sci U S A. 2012, 109: E2127-E2133. 10.1073/pnas.1203530109.PubMedCentralCrossRefPubMed

Peebles KA, Lee JM, Mao JT, Hazra S, Reckamp KL, Krysan K, Dohadwala M, Heinrich EL, Walser TC, Cui X, et al.: Inflammation and lung carcinogenesis: applying findings in prevention and treatment. Expert Rev Anticancer Ther. 2007, 7: 1405-1421. 10.1586/14737140.7.10.1405.CrossRefPubMed

Huang Y, Sadee W: Membrane transporters and channels in chemoresistance and -sensitivity of tumor cells. Cancer Lett. 2006, 239: 168-182. 10.1016/j.canlet.2005.07.032.CrossRefPubMed

Sasazawa Y, Futamura Y, Tashiro E, Imoto M: Vacuolar H + −ATPase inhibitors overcome Bcl-xL-mediated chemoresistance through restoration of a caspase-independent apoptotic pathway. Cancer Sci. 2009, 100: 1460-1467. 10.1111/j.1349-7006.2009.01194.x.CrossRefPubMed

Nishisho T, Hata K, Nakanishi M, Morita Y, Sun-Wada GH, Wada Y, Yasui N, Yoneda T: The a3 isoform vacuolar type H(+)-ATPase promotes distant metastasis in the mouse B16 melanoma cells. Mol Cancer Res. 2011, 9: 845-855. 10.1158/1541-7786.MCR-10-0449.CrossRefPubMed

Hendrix A, Sormunen R, Westbroek W, Lambein K, Denys H, Sys G, Braems G, Van den Broecke R, Cocquyt V, Gespach C, et al.: V-ATPase expression and activity is required for Rab27B-dependent invasive growth and metastasis of breast cancer. Int J Cancer. 2013, 133 (4): 843-845. 10.1002/ijc.28079.CrossRefPubMed

Hinton A, Sennoune SR, Bond S, Fang M, Reuveni M, Sahagian GG, Jay D, Martinez-Zaguilan R, Forgac M: Function of a subunit isoforms of the V-ATPase in pH homeostasis and in vitro invasion of MDA-MB231 human breast cancer cells. J Biol Chem. 2009, 284: 16400-16408. 10.1074/jbc.M901201200.PubMedCentralCrossRefPubMed

10.

Straud S, Zubovych I, De Brabander JK, Roth MG: Inhibition of iron uptake is responsible for differential sensitivity to V-ATPase inhibitors in several cancer cell lines. PLoS One. 2010, 5: e11629-10.1371/journal.pone.0011629.PubMedCentralCrossRefPubMed

11.

Huang L, Lu Q, Han Y, Li Z, Zhang Z, Li X: ABCG2/V-ATPase was associated with the drug resistance and tumor metastasis of esophageal squamous cancer cells. Diagn Pathol. 2012, 7: 180-10.1186/1746-1596-7-180.PubMedCentralCrossRefPubMed

12.

Campa D, Muller P, Edler L, Knoefel L, Barale R, Heussel CP, Thomas M, Canzian F, Risch A: A comprehensive study of polymorphisms in ABCB1, ABCC2 and ABCG2 and lung cancer chemotherapy response and prognosis. Int J Cancer. 2012, 131: 2920-2928. 10.1002/ijc.27567.CrossRefPubMed

13.

Yamazaki R, Nishiyama Y, Furuta T, Hatano H, Igarashi Y, Asakawa N, Kodaira H, Takahashi H, Aiyama R, Matsuzaki T, et al.: Novel acrylonitrile derivatives, YHO-13177 and YHO-13351, reverse BCRP/ABCG2-mediated drug resistance in vitro and in vivo. Mol Cancer Ther. 2011, 10: 1252-1263. 10.1158/1535-7163.MCT-10-0874.CrossRefPubMed

14.

Albermann N, Schmitz-Winnenthal FH, Z'Graggen K, Volk C, Hoffmann MM, Haefeli WE, Weiss J: Expression of the drug transporters MDR1/ABCB1, MRP1/ABCC1, MRP2/ABCC2, BCRP/ABCG2, and PXR in peripheral blood mononuclear cells and their relationship with the expression in intestine and liver. Biochem Pharmacol. 2005, 70: 949-958. 10.1016/j.bcp.2005.06.018.CrossRefPubMed

15.

Modok S, Mellor HR, Callaghan R: Modulation of multidrug resistance efflux pump activity to overcome chemoresistance in cancer. Curr Opin Pharmacol. 2006, 6: 350-354. 10.1016/j.coph.2006.01.009.CrossRefPubMed

16.

Nakagawa H, Saito H, Ikegami Y, Aida-Hyugaji S, Sawada S, Ishikawa T: Molecular modeling of new camptothecin analogues to circumvent ABCG2-mediated drug resistance in cancer. Cancer Lett. 2006, 234: 81-89. 10.1016/j.canlet.2005.05.052.CrossRefPubMed

17.

Otto C, Csanadi A, Fisch P, Werner M, Kayser G: Molecular modeling and description of a newly characterized activating mutation of the EGFR gene in non-small cell lung cancer. Diagn Pathol. 2012, 7: 146-10.1186/1746-1596-7-146.PubMedCentralCrossRefPubMed

18.

Ohe M, Yokose T, Sakuma Y, Miyagi Y, Okamoto N, Osanai S, Hasegawa C, Nakayama H, Kameda Y, Yamada K, Isobe T: Stromal micropapillary component as a novel unfavorable prognostic factor of lung adenocarcinoma. Diagn Pathol. 2012, 7: 3-10.1186/1746-1596-7-3.PubMedCentralCrossRefPubMed

19.

Perez-Sayans M, Garcia-Garcia A, Scozzafava A, Supuran CT: Inhibition of V-ATPase and carbonic anhydrases as interference strategy with tumor acidification processes. Curr Pharm Des. 2012, 18: 1407-1413. 10.2174/138161212799504876.CrossRefPubMed

20.

Wiedmann RM, von Schwarzenberg K, Palamidessi A, Schreiner L, Kubisch R, Liebl J, Schempp C, Trauner D, Vereb G, Zahler S, et al.: The V-ATPase-inhibitor archazolid abrogates tumor metastasis via inhibition of endocytic activation of the Rho-GTPase Rac1. Cancer Res. 2012, 72: 5976-5987. 10.1158/0008-5472.CAN-12-1772.CrossRefPubMed

21.

Sennoune SR, Bakunts K, Martinez GM, Chua-Tuan JL, Kebir Y, Attaya MN, Martinez-Zaguilan R: Vacuolar H + −ATPase in human breast cancer cells with distinct metastatic potential: distribution and functional activity. Am J Physiol Cell Physiol. 2004, 286: C1443-C1452. 10.1152/ajpcell.00407.2003.CrossRefPubMed

22.

Niikura K: Effect of a V-ATPase inhibitor, FR202126, in syngeneic mouse model of experimental bone metastasis. Cancer Chemother Pharmacol. 2007, 60: 555-562. 10.1007/s00280-006-0401-8.CrossRefPubMed

23.

Breedveld P, Pluim D, Cipriani G, Dahlhaus F, van Eijndhoven MA, de Wolf CJ, Kuil A, Beijnen JH, Scheffer GL, Jansen G, et al.: The effect of low pH on breast cancer resistance protein (ABCG2)-mediated transport of methotrexate, 7-hydroxymethotrexate, methotrexate diglutamate, folic acid, mitoxantrone, topotecan, and resveratrol in in vitro drug transport models. Mol Pharmacol. 2007, 71: 240-249.CrossRefPubMed

24.

Li L, Sham YY, Bikadi Z, Elmquist WF: pH-Dependent transport of pemetrexed by breast cancer resistance protein. Drug Metab Dispos. 2011, 39: 1478-1485. 10.1124/dmd.111.039370.CrossRefPubMed

25.

Mahoney BP, Raghunand N, Baggett B, Gillies RJ: Tumor acidity, ion trapping and chemotherapeutics. I. Acid pH affects the distribution of chemotherapeutic agents in vitro. Biochem Pharmacol. 2003, 66: 1207-1218. 10.1016/S0006-2952(03)00467-2.CrossRefPubMed

26.

Pastor-Soler N, Beaulieu V, Litvin TN, Da Silva N, Chen Y, Brown D, Buck J, Levin LR, Breton S: Bicarbonate-regulated adenylyl cyclase (sAC) is a sensor that regulates pH-dependent V-ATPase recycling. J Biol Chem. 2003, 278: 49523-49529. 10.1074/jbc.M309543200.PubMedCentralCrossRefPubMed

27.

Recchi C, Chavrier P: V-ATPase: a potential pH sensor. Nat Cell Biol. 2006, 8: 107-109. 10.1038/ncb0206-107.CrossRefPubMed

28.

Kim HS, Oh JM, Luan S, Carlson JE, Ahn SJ: Cold stress causes rapid but differential changes in properties of plasma membrane H(+)-ATPase of camelina and rapeseed. J Plant Physiol. 2013, 170 (9): 828-837. 10.1016/j.jplph.2013.01.007.CrossRefPubMed

29.

Tang RJ, Liu H, Yang Y, Yang L, Gao XS, Garcia VJ, Luan S, Zhang HX: Tonoplast calcium sensors CBL2 and CBL3 control plant growth and ion homeostasis through regulating V-ATPase activity in Arabidopsis. Cell Res. 2012, 22: 1650-1665. 10.1038/cr.2012.161.PubMedCentralCrossRefPubMed

30.

Torigoe T, Izumi H, Ishiguchi H, Uramoto H, Murakami T, Ise T, Yoshida Y, Tanabe M, Nomoto M, Itoh H, Kohno K: Enhanced expression of the human vacuolar H + −ATPase c subunit gene (ATP6L) in response to anticancer agents. J Biol Chem. 2002, 277: 36534-36543. 10.1074/jbc.M202605200.CrossRefPubMed

31.

Nasiri N, Shokri E, Nematzadeh GA: Aeluropus littoralis NaCl-induced vacuolar H(+)-ATPase subunit c: molecular cloning and expression analysis. Genetika. 2012, 48: 1380-1388.PubMed

Title: The expression of V-ATPase is associated with drug resistance and pathology of non-small-cell lung cancer
Authors: Qiang Lu
Sha Lu
Lijun Huang
Ting Wang
Yi Wan
Chang Xi Zhou
Cunhai Zhang
Zhipei Zhang
Xiaofei Li
Publication date: 01-12-2013
Publisher: BioMed Central
Published in: Diagnostic Pathology / Issue 1/2013
Electronic ISSN: 1746-1596
DOI: https://doi.org/10.1186/1746-1596-8-145

ACC 2024 Congress

Springer Medicine

The expression of V-ATPase is associated with drug resistance and pathology of non-small-cell lung cancer

Abstract

Objective

Methods

Results

Conclusions

Virtual slides

ACC 2024 Congress

Springer Medicine

Abstract

Objective

Methods

Results

Conclusions

Virtual slides

Please log in to get access to this content

Other articles of this Issue 1/2013

Sertoliform cystadenoma: a rare benign tumour of the rete testis

Primary submucosal nodular plasmacytoma of the stomach: a poorly recognized variant of gastric lymphoma

Dramatic early event in chronic allograft nephropathy: increased but not decreased expression of MMP-9 gene

Endobronchial endometriosis presenting as central-type lung cancer: a case report

Human papillomavirus genotypes in human immunodeficiency virus-positive patients with anal pathology in Madrid, Spain

Triggering receptor expressed on myeloid cells − 1 (Trem-1) on blood neutrophils is associated with cytokine inducibility in human E. coli sepsis